anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention relates to a method for preparing a medicine, particularly to a method for preparing a medicine for treating alopecia areata. The precursor of the medicine is basic culture media which contain 15% of human AB type serum. The basal culture media are formed from components with the proportion: 15 ml of human AB type serum, 85 ml of low-sugar culture media (DMEM), 0.24g of hepes, 0.2g of sodium bicarbonate and 0.03gL of glutamine. The basal culture media are used for cultivating low passage papillary cells of human hair, culture supernatant of the low passage papillary cells of human hair is collected as conditioned media for the papillary cells of human hair, and the collected conditioned media for the papillary cells of human hair are prepared into dry powder. The medicine prepared by the present invention has significant therapeutic effect during the treatment of alopecia areata, and the therapeutic effect is obviously better than the therapeutic effect of other medicines, such as hormone on the alopecia areata. In addition, the cells and the culture media, which are used by the medicine do not have antigenicity to human bodies. When the medicine is used for the human bodies, the human bodies do not have any allergic reaction. The present invention overcomes the side effect which is brought to the human bodies by the hormone therapy of the alopecia areata.
The present invention provides compositions comprising an RNAi-inducing entity targeted to an influenza virus transcript and any of a variety of delivery agents. The invention further includes methods of use of the compositions for inhibiting a biological activity of an influenza virus and/or for treatment or prevention of influenza. The invention provides target portion sequences that are favorably conserved for RNAi across a plurality of influenza virus A strains isolated from human hosts and/or avian hosts and RNAi-inducing entities, e.g., siRNAs and shRNAs, targeted to such favorably conserved target portions. The invention provides a variety of nucleic acids comprising sequences identical or complementary to at least a portion of one or more of these favorably conserved target portion sequences. The invention further provides methods and compositions for delivering RNAi-inducing agents to an organ or tissue of a mammalian subject, e.g., to the lung. Methods of diagnosing influenza and determining the susceptibility of an influenza virus to inhibition by an RNAi-inducing agent are also provided. Transgenic animals that express an RNAi-inducing agent targeted to an influenza gene are another aspect of the invention.
Visual hallucinations can increase the burden of disease for both patients with Parkinson's disease and their caregivers. Multiple neurotransmitters have been implicated in the neuropathology of visual hallucinations, which provide targets for treatment and prevention. In this study, we assessed the association between cholinergic denervation and visual hallucinations in Parkinson's disease in vivo, using PET imaging of the cholinergic system. A total of 38 patients with Parkinson's disease participated in this study. A group of 10 healthy subjects, matched for age, sex and education, was included for comparison. None of the participants used cholinergic drugs. Thirteen patients who had experienced visual hallucinations in the past month (VH+) were compared with 20 patients who had never experienced visual hallucinations in their lives (VH-). Cholinergic system integrity was assessed with PET imaging using 18F-fluoroethoxybenzovesamicol as the tracer. We assessed the differences in tracer uptake between groups by cluster-based analysis and by analysis of predefined regions of interest consisting of the ventral visual stream, the dorsal attentional network, the ventral attentional network and the lateral geniculate nucleus and mediodorsal nucleus of the thalamus. The Parkinson's disease group (n = 38) showed an extensive pattern of decreased tracer uptake throughout the brain compared with the controls (n = 10). Within the Parkinson's disease group, the VH+ group (n = 13) showed a cluster of decreased tracer uptake compared with the VH- group (n = 20), which covered most of the left ventral visual stream and extended towards superior temporal areas. These results were mirrored in the regions of interest-based analysis, in which the VH+ group showed the strongest deficits in the left inferior temporal gyrus and the left superior temporal gyrus compared with the VH- group. Visual hallucinations in Parkinson's disease are associated with a marked cholinergic deficiency in the left ventral visual stream and the left superior temporal lobe, in addition to an extensive global cholinergic denervation in the general Parkinson's disease population.
An nstrumented thoracic model for measuring the effects of impacts is provided. The model has simulated skeletal components, simulated tissue, simulated internal organs, and sensors that are optimally placed in the simulated tissue and organs, said simulated organs and said simulated skeletal components. Simulated human tissue is made of a modified ballistic gelatin, comprising ordinance gelatin, chilled water and an antimicrobial agent in a desired volume or weight percentage. The resulting mixture is then poured into a container or mold having the desired tissue shape, and then chilled until the mixture has set. Simulated lung tissue is made of the modified ballistic gelatin, but also incorporates nicrospheres to approximate the density and modality of the lungs. The sensors of the thoracic model are optimally placed using primary component analysis
Risk Summary

Ipratropium is negligibly absorbed systemically following oral inhalation; therefore, maternal use is not expected to result in fetal exposure to the drug [see Clinical Pharmacology (12.3)]. There is limited experience with ipratropium bromide use in pregnant women. Published literature, including cohort studies, case control studies and case series, over several decades have not identified a drug associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Based on animal reproduction studies, no evidence of structural alterations was observed when ipratropium bromide was administered to pregnant mice, rats and rabbits during organogenesis at doses up to approximately 200, 40,000, and 10,000 times, respectively, the maximum recommended human daily inhalation dose (MRHDID) in adults (see Data).

The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

Data

Animal Data

In animal reproduction studies, oral and inhalation administration of ipratropium bromide to pregnant mice, rats and rabbits during the period of organogenesis did not show evidence of fetal structural alterations. The ipratropium bromide dose in oral studies in mice, rats, and rabbits was up to approximately 200, 40,000, and 10,000 times, respectively, the MRHDID in adults (on a mg/m2 basis at maternal doses of 10, 1000, and 125 mg/kg/day, respectively). The ipratropium bromide dose in inhalation studies in rats and rabbits was up to approximately 60 and 140 times, respectively, the MRHDID in adults (on a mg/m2 basis at maternal doses of 1.5 and 1.8 mg/kg/day, respectively). Embryotoxicity was observed as increased resorption in rats at oral doses approximately 3600 times the MRHDID in adults (on a mg/m2 basis at maternal doses of 90 mg/kg/day and above). This effect is not considered relevant to human use due to the large doses at which it was observed and the difference in route of administration.
Acute Myeloid Leukemia (AML) is an aggressive hematological malignancy with a median age at diagnosis of 65 years. Outcomes of AML in elderly population remain unsatisfactory with low rates of complete remission, poor disease-free and overall survival. Therapeutic management of older patients with AML deals with patient-related features (i.e. comorbid conditions and performance status) as well as disease-related prognostic factors (i.e. cytogenetics and molecular genetics). Even if allogeneic hematopoietic-cell transplantation provides the strongest antineoplasic effect, this treatment option remains limited for older patients owing to toxicities, the development of significant graft-versus-host disease (GVHD) and logistics of donor availability. More recently, micro-transplantation has emerged as an alternative strategy based on the infusion of mobilized HLA-mismatched related donor cells after induction chemotherapy, thus exerting a graft-versus-leukemia effect without substantial donor engraftment and GVHD. Therefore, there is much of interest in investigating the efficacy and the safety of this method for older patients with AML who are not candidates for allogeneic stem cell transplantation.
This display system is provided with a sensor, a projector, and a control means. The sensor detects user information for calculating a state relating to sleep of a user. The user information is, for instance, biological information, such as pulse rate. The projector displays, by means of projection, a predetermined image. For instance, the projector displays, by means of projection, an image on a ceiling by projecting the image upward. The control means controls the projector corresponding to the sleep-related state calculated on the basis of the user information.
Within the active virtual reality group virtual environment, participants will play the game Bearblast using Oculus Go Headset for patients 8-21 years old. In BearBlast, participants travel on a pre-set path through an interactive environment.
The invention discloses traditional Chinese medicine preparations used for treating psoriasis. The medicine preparations are prepared from the medicine materials of, by weight: 20-35 parts of Japanese pogodatree flower, 20-35 parts of lalang grass rhizome, 6-18 parts of red peony root, 10-40 parts of common yam rhizome, 6-30 parts of buffalo horn, 6-15 parts of white peony root, 4-10 parts of submature bitter orange, 6-18 parts of salvia miltiorrhiza, and 6-20 parts of Mongolian milkvetch root. The medicine can be prepared into powders, capsule preparations, tablets, instant granules, and oral liquid preparations. The medicine materials selected by the invention have functions of heat clearing, blood cooling, detoxifying, stasis removing, and pain relieving. The medicine preparations are used for treating psoriasis with a variety of causes. As a result of clinical applications, the medicine preparations have the advantages of low treatment cost, no toxic or side effect, and good treatment effect.
Participants will have a 1 in 2 chance to get the active treatment device post-operatively. The device will be attached to the post-operative dressing. The device is an Endonovo SofPulse that emits a pulsed electromagnetic field (PEMF). Single blind randomization.
Diclofenac sodium extended-release tablets, USP is a benzeneacetic acid derivative. Diclofenac sodium extended-release tablets of 100 mg (pink) are available for oral administration. Diclofenac sodium is a white or slightly yellowish crystalline powder and is sparingly soluble in water at 25°C. The chemical name is 2-[(2,6-dichlorophenyl)amino] benzeneacetic acid, monosodium salt. The molecular weight is 318.14. Its molecular formula is C14H10Cl2NNaO2, and it has the following structural formula:

The inactive ingredients in diclofenac sodium extended-release tablets include: carnauba wax, cetostearyl alcohol, colloidal silicon dioxide, compressible sugar, copovidone, gum acacia, hydroxypropyl methylcellulose, iron oxide red, magnesium stearate, polyethylene glycol, povidone, sucrose, talc, titanium dioxide.

  


Meets USP Dissolution Test 2.
The present invention relates to beverages comprising living probiotics and multi-layered drop pills for use. In particular to a multi-layer (for example, 2-5 layers such as 2-4 layers such as 3 layers) dripping pill, which comprises an inner layer, a middle layer and an outer layer which are concentric circles, wherein the inner layer is a homogeneous mixture formed by probiotic powder and oily substances, the middle layer is oily substances, and the outer layer is a rubber shell formed by dripping and drying a glue solution formed by a polymer material, a plasticizer and water. The live probiotic is a live microorganism beneficial to the gastrointestinal tract and is selected from the group consisting of bifidobacterium, lactobacillus, streptococcus, lactococcus, leuconostoc, propionibacterium, pediococcus, staphylococcus, bacillus and kluyveromyces. Also relates to beverages comprising such a multi-layered (e.g. 2-5 layers, e.g. 2-4 layers, e.g. 3 layers) drop pill of live probiotics. The beverages and multi-layered (e.g., 2-5 layers, e.g., 2-4 layers, e.g., 3 layers) drop pills of the live probiotic of the present invention exhibit excellent technical effects as described in the specification.
B-cell acute lymphoblastic leukaemia (B-ALL) is the most prevalent hematologic malignancy in children and a leading cause of mortality. Managing B-ALL remains challenging due to its heterogeneity and relapse risk. This study aimed to delineate the molecular features of paediatric B-ALL and explore the clinical utility of circulating tumour DNA (ctDNA). We analysed 146 patients with paediatric B-ALL who received systemic chemotherapy. The mutational landscape was profiled in bone marrow (BM) and plasma samples using next-generation sequencing. Minimal residual disease (MRD) testing on day 19 of induction therapy evaluated treatment efficacy. RNA sequencing identified gene fusions in 61% of patients, including 37 novel fusions. Specifically, the KMT2A-TRIM29 novel fusion was validated in a boy who responded well to initial therapy but relapsed after 1 year. Elevated mutation counts and maximum variant allele frequency in baseline BM were associated with significantly poorer chemotherapy response (p = 0.0012 and 0.028, respectively). MRD-negative patients exhibited upregulation of immune-related pathways (p < 0.01) and increased CD8+ T cell infiltration (p = 0.047). Baseline plasma ctDNA exhibited high mutational concordance with the paired BM samples and was significantly associated with chemotherapy efficacy. These findings suggest that ctDNA and BM profiling offer promising prognostic insights for paediatric B-ALL management.
Pancreatic adenocarcinoma (PAAD) is a notably aggressive malignancy with limited treatment options and an unfavorable prognosis for patients. We aimed to investigate molecular mechanisms by which Sam's pointed domain-containing ETS transcription factor (SPDEF) exerts effects on PAAD progression. We analyzed differentially expressed genes (DEGs) and their integration with ETS family members using the The Cancer Genome Atlas (TCGA) database, hence identifying SPDEF as a core gene in PAAD. Kaplan-Meier survival analysis confirmed SPDEF's prognostic potential. In vitro experiments validated the association with cell proliferation and apoptosis, affecting pancreatic cancer cell dynamics. We detected increased SPDEF expression in PAAD tumor samples. Our in vitro studies revealed that SPDEF regulates mRNA and protein expression levels, and significantly affects cell proliferation. Moreover, SPDEF was associated with reduced apoptosis and enhanced cell migration and invasion. In-depth analysis of SPDEF-targeted genes revealed four crucial genes for advanced prognostic model, among which S100A16 was significantly correlated with SPDEF. Mechanistic analysis showed that SPDEF enhances the transcription of S100A16, which in turn enhances PAAD cell migration, proliferation, and invasion by activating the PI3K/AKT signaling pathway. Our study revealed the critical role of SPDEF in promoting PAAD by upregulating S100A16 transcription and stimulating the PI3K/AKT signaling pathway. This knowledge deepened our understanding of pancreatic cancer's molecular progression and unveiled potential therapeutic strategies targeting SPDEF-driven pathways.
PURPOSE: To obtain a topically applicable composition containing a specific α-pyrone compound and intended to induce and stimulate the growth of hair and retard the loss and decrease in the hair. CONSTITUTION: This composition contains 0.05-10 wt.% (preferably 0.1-6 wt.%) of an α-pyrone compound of the formula [R1 is H, a 1-4C alkoxy; R2 is H, hydroxyl; R3 is a 1-4C alkyl, (substituted) styryl, etc.; wherein when R2 is hydroxyl, R3 is non-substituted phenethyl) in a medium comprising water and/or an organic solvent such as ethanol. Preferable examples of the compound include kavaine and 5-methyl-δ-valerolactone. The kavaine (derivative) exists in kava of a Polynesian plant in a natural state, and is obtained by an extraction method. The 5-methyl-δ-valerolactone exists especially in Avena-Sativa, and is obtained by an extraction method.
Patients in the aIMT (acute IMT) experimental group will complete a single session of IMT guided by a physical therapist within 30 minutes of anesthesia induction in addition to standard of care. The adjustable pressure threshold training device to provide resistance during inspiration will be used. Subjects will complete 5 sets of 5 maximal volume and speed breaths, and rest 1 minute between sets. The training intensity will be set at 70% of MIP.
BACKGROUND: Air pollution has several negative health effects. Particulate matter (PM) is a pollutant that is often linked to health adversities. PM2.5 (PM with an aerodynamic diameter of ≤2.5μm) exposure has been associated with negative cardiovascular (CV) outcomes. However, the impact of PM10 (PM with an aerodynamic diameter of ≤10μm) exposure is often overlooked due to its limited ability to pass the alveolar barrier. This study aims to assess the association between PM10 exposure and risk of myocardial infarction (MI) amongst adults (≥18 years of age) as this has been poorly studied.
METHODS: The study protocol was published on the International Prospective Register of Systematic Reviews (PROSPERO) (CRD42023409796) on March 31, 2023. Literature searches were conducted on 4 databases (Ovid Medline, Embase, CINAHL (Cumulative Index to Nursing and Allied Health Literature), and Web of Science) on January 17, 2023, for studies looking at associations between PM and MI. English studies from all time periods were assessed. Studies selected for review were time-series, case-crossover, and cohort studies which investigated the risk of MI as an outcome upon PM10 exposure. The quality of evidence was assessed using Cochrane's Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach. Data for different risk outcomes (risk ratio (RR), odds ratio (OR), hazard ratio (HR)) and 3 lags was meta-analyzed using an inverse variance statistical analysis using a random effects model. The pooled effect sizes and the 95% confidence intervals (CIs) were reported in forest plots.
RESULTS: Among the 1,099 studies identified, 41 were included for review and 23 were deemed eligible for meta-analysis. Our analysis revealed that there is an increased risk (OR = 1.01; 95% CI:1.00-1.02) of MI with a 10 μg/m3 increase in PM10 after a lag 0 and lag 1 delay.
CONCLUSIONS: Our findings indicate that PM10 exposure is associated with an increased risk of MI. This can aid in informing environmental policy-making, personal-level preventative measures, and global public health action.
PURPOSE: To shorten preparation time and facilitate the management of asepsis, heat freeness and differences between lots and facilities by preserving and sealing a calculated necessary amount of all non-isotope stuffs in a vessel in advance. CONSTITUTION: The eventual amount of all stuffs necessary for labeling reaction to be obtained, excluding radioisotopes, are calculated and measured in advance and if necessary, reaction solvent and subsidiary stuffs, etc., are also measured and mixed. They are preserved and sealed in each vessel of closed system and sterilizing filters are placed in intake and exhaust ports. All the reaction process is done with the operation of an open/close cock provided in between a stuff preservation vessel and a reaction vessel and with depressurization of non-reactive gas for transportation (N2 , He, etc.). By repeating transportation to corresponding vessel, separation extraction, solvent removal and necessary heating, an eventual labeled compound is obtained.  This, prefilled kit is administered for all stuffs, the quality of vessel and the like, amount, etc., so that asepsis, heat freeness, airtightness and the quality of eventual matter are constant.
The present invention relates to a pharmaceutical and health food composition containing osajin or pomiferin, separated from an osage orange, as active ingredient for preventing or treating diabetes. Osajin and pomiferin have an excellent effect of alleviating diabetes such as reduction of a level of blood sugar and triglyceride and weight control. Therefore, osajin and pomiferin can be used as health-functional and natural substances for treating or alleviating diabetes. Moreover, a detailed method of extraction and fraction is suggested by the present invention. A compound of osajin and pomiferin which is contained in the oasge orange in a large amount and has excellent activity is expected to be applied as an economical and highly functional raw material. The compound of osajin and pomiferin is represented by Chemical Formula 1 or 2.
Subjects will be recruited in accordance with inclusion and exclusion criteria listed below. Subjects will be assigned to one of two different grain product 'exposure' groups - Group 1 will receive predominantly Whole Grain (WG) products and Group 2 will receive predominantly Refined Grain (RG) products (ratio of WG to RG assignment will be 2:1). For a 6-week exposure period, subjects will receive weekly market baskets of grain products consisting of breakfast cereals, breads, snack items, and side dishes with the target of providing whole grains at a level of 85% of grain intake for the WG group (this exceeds the current Dietary Guideline recommendation of 50%) and 15% for the RG group (this is the current estimated intake for U.S. adults). Before and after grain exposure, subjects will rate the acceptability and liking of numerous grain products. To accomplish this, subjects will participate in sensory evaluation tests using these products, and they will provide information using validated questionnaires and take implicit association tests. During the 6-week study period, subjects will record use of the market basket grain products, and provide subjective scores for taste, convenience, nutrition, and general liking. The quality of the total dietary intake will be assessed using unannounced 24-h recalls. Biological samples will also be collected from subjects. Blood and urine samples will be collected to evaluate risk factors of chronic disease, and biomarkers of whole grain intake, fruits and vegetables. Saliva and fecal samples will be collected to measure changes in gut microbiota and to measure metabolites of bacterial fermentation. Breath hydrogen tests will be conducted to measure bacterial fermentation. Two weeks after the end of the intervention period, subjects will participate in a nominal group session to identify significant barriers and facilitators to inclusion of grain products into their diets.